Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies

Next Previous
Trial Profile

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ripretinib (Primary)
  • Indications Dermatofibrosarcoma; Gastrointestinal stromal tumours; Germ cell cancer; Glioblastoma; Glioma; Haematological malignancies; Hypereosinophilic syndrome; Malignant melanoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Nerve sheath neoplasms; Non-small cell lung cancer; Penile cancer; Soft tissue sarcoma; Solid tumours; Systemic mastocytosis
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Deciphera Pharmaceuticals

    • Most Recent Events

    • 17 Nov 2022 Status changed from active, no longer recruiting to completed.
    • 21 Dec 2021 According to a Deciphera Pharmaceuticals media release, based on the results from INVICTUS and Phase 1 study of QINLOCK, the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for QINLOCK (ripretinib) in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
    • 17 Sep 2021 According to a Deciphera Pharmaceuticals media release, company will also host an investor event on 17 September 2021, to discuss the data of this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top